Discovery and Development of Vital
Medicines for Tropical Diseases
60° Pharmaceuticals (60P) was founded in 2010 with a mission to discover, develop, and distribute new medicines for the prevention of tropical diseases.
Our core business is delivering tropical disease drug research and development while providing an attractive return for investors.
60P has embraced an approach to reduce the time, cost, and risk needed to build a portfolio of drug discovery and development projects. We are in collaboration with leading research institutions in the United States, Australia, and Singapore to discover and develop medications for dengue fever and malaria prevention.
We apply the same passion, energy, and culture of innovation that make us commercially successful to making a difference in the world. We are committed to finding the tools and strategies that will help us overcome some of the planet’s greatest health challenges.
FORWARD LOOKING STATEMENTS: This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our financial guidance, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “targets,” “forecasts,” “estimates” and similar expressions in conjunction with, among other things obtaining future product sales, discussions of the Company’s outlook, financial performance or financial condition, growth strategy, government development or procurement contracts or awards, government appropriations, manufacturing capabilities, product development, or regulatory approvals or expenditures and plans to increase our operational efficiencies and cost structure are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.